SG Americas Securities LLC Has $241,000 Position in Omeros Co. (NASDAQ:OMER)

SG Americas Securities LLC lifted its holdings in shares of Omeros Co. (NASDAQ:OMER) by 21.2% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 24,361 shares of the biopharmaceutical company’s stock after buying an additional 4,257 shares during the period. SG Americas Securities LLC’s holdings in Omeros were worth $241,000 at the end of the most recent quarter.

Several other hedge funds also recently modified their holdings of OMER. Barclays PLC boosted its position in Omeros by 121.3% during the third quarter. Barclays PLC now owns 94,640 shares of the biopharmaceutical company’s stock valued at $376,000 after purchasing an additional 51,873 shares during the last quarter. Geode Capital Management LLC raised its stake in shares of Omeros by 0.5% during the 3rd quarter. Geode Capital Management LLC now owns 1,339,251 shares of the biopharmaceutical company’s stock worth $5,318,000 after purchasing an additional 6,839 shares in the last quarter. MML Investors Services LLC boosted its holdings in shares of Omeros by 19.2% in the 3rd quarter. MML Investors Services LLC now owns 18,600 shares of the biopharmaceutical company’s stock valued at $74,000 after buying an additional 3,000 shares during the last quarter. Jane Street Group LLC grew its stake in shares of Omeros by 15.9% in the third quarter. Jane Street Group LLC now owns 58,277 shares of the biopharmaceutical company’s stock valued at $231,000 after buying an additional 8,010 shares in the last quarter. Finally, Wellington Management Group LLP acquired a new position in Omeros during the third quarter worth $305,000. Institutional investors own 48.79% of the company’s stock.

Analysts Set New Price Targets

A number of analysts have commented on OMER shares. Needham & Company LLC reiterated a “hold” rating on shares of Omeros in a research note on Friday, January 17th. RODMAN&RENSHAW upgraded shares of Omeros to a “strong-buy” rating in a research note on Thursday, November 14th. Rodman & Renshaw assumed coverage on Omeros in a research note on Thursday, November 14th. They issued a “buy” rating and a $9.00 price target for the company. D. Boral Capital reaffirmed a “buy” rating and issued a $36.00 price objective on shares of Omeros in a research note on Thursday, January 16th. Finally, Cantor Fitzgerald reiterated a “neutral” rating on shares of Omeros in a research note on Thursday, November 14th. Three research analysts have rated the stock with a hold rating, two have given a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, Omeros currently has a consensus rating of “Moderate Buy” and a consensus target price of $22.50.

Omeros Stock Performance

Omeros stock opened at $9.08 on Friday. The firm has a market cap of $526.19 million, a price-to-earnings ratio of -3.93 and a beta of 1.98. The firm has a 50 day moving average price of $9.69 and a two-hundred day moving average price of $6.43. Omeros Co. has a 52-week low of $2.61 and a 52-week high of $13.60.

About Omeros

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company’s products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19.